Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
New uses for milk-derived products for eradication of Helicobacter pylori infection and gastro-intestinal site-specific delivery of active agents. Helicobacter pylori is the most significant bacterial pathogen in the world, infecting 50% globally. Current treatments are inducing rapid antibiotic resistance and are thus becoming increasingly less effective. The infection is acquired in childhood and new methods to prevent and/or treat the infection, minimising acquisition of antibiotic resistance ....New uses for milk-derived products for eradication of Helicobacter pylori infection and gastro-intestinal site-specific delivery of active agents. Helicobacter pylori is the most significant bacterial pathogen in the world, infecting 50% globally. Current treatments are inducing rapid antibiotic resistance and are thus becoming increasingly less effective. The infection is acquired in childhood and new methods to prevent and/or treat the infection, minimising acquisition of antibiotic resistance are urgently required. This project seeks to develop new ways of doing this that combine novel antibacterials with techniques to deliver them (and monitor this delivery) as well as modify the complex protective habitat in the stomach.Read moreRead less